Comprehensive tissue repair stack combining BPC-157, TB-500, KPV, and GHK-Cu for accelerated healing, GI support, inflammatory modulation, and cellular regeneration. Prescription required.
BPC-157 is a pentadecapeptide — a sequence of 15 amino acids — derived from a protein found in gastric juice. It does not occur naturally in isolation in the body, but its constituent sequence has been identified in human gastric juice and studied extensively in preclinical and clinical settings.
In clinical settings, BPC-157 has been studied for its potential role in modulating the nitric oxide (NO) system, promoting angiogenesis, and interacting with growth hormone receptors. These mechanisms may support tissue repair processes across multiple tissue types, including muscle, tendon, ligament, and gastrointestinal mucosa.
Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Nitric oxide (NO) system modulation | Vasodilation and tissue perfusion |
| Angiogenesis promotion | New blood vessel formation |
| Growth hormone receptor interaction | Tissue repair signaling |
| GI mucosal protection | Gut barrier integrity |
| Anti-inflammatory pathways | Reduced systemic inflammation |
| Tendon/ligament repair signaling | Accelerated recovery |
TB-500 is a synthetic analogue of the naturally occurring peptide Thymosin Beta-4, derived from a conserved actin-sequestering domain. It is found in high concentrations in platelets and wound fluid, suggesting a role in the body's repair response.
In clinical and preclinical settings, TB-500 has been studied for its role in promoting cell migration, angiogenesis, and tissue remodeling through actin-binding activity. It may support stem cell recruitment and anti-apoptotic pathways relevant to musculoskeletal and soft tissue recovery. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Actin binding | Increased cell migration and repair |
| Angiogenesis | New blood vessel formation |
| Anti-inflammatory signaling | Reduced tissue inflammation |
| Stem cell recruitment | Regeneration of damaged tissue |
| Anti-apoptotic activity | Reduced cell death in injured tissue |
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH). It has been studied for its anti-inflammatory and GI protective properties in preclinical and clinical settings.
KPV works through melanocortin pathway modulation and NF-κB inhibition, with potential applications in inflammatory bowel conditions and gut barrier integrity support. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| NF-κB inhibition | Reduced inflammatory cytokines |
| Melanocortin pathway modulation | Immune regulation |
| Antimicrobial peptide activity | Direct pathogen suppression |
| Intestinal epithelial protection | Reduced gut inflammation |
| Immune cell modulation | Lower neutrophil/macrophage activation |
GHK-Cu is a naturally occurring copper-binding tripeptide derived from the peptide GHK. It forms when GHK binds Copper. The complex acts as a signaling and copper-transport molecule that influences tissue repair, inflammation, and gene expression.
In clinical settings, GHK-Cu has been studied for its role in activating fibroblasts, modulating gene expression, and promoting antioxidant pathways. It may support collagen synthesis, tissue repair, and skin regeneration through multiple mechanisms. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Copper chelation and delivery | Activates copper-dependent enzymes |
| Gene expression modulation | Promotes regenerative pathways |
| Fibroblast activation | Increases collagen and elastin |
| Anti-inflammatory signaling | Suppresses NF-κB cytokine pathways |
| Antioxidant effects | Reduces oxidative stress |
| Wound healing acceleration | Enhanced tissue remodeling |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with BPC-157 protocol candidates in clinical practice:
Tissue Repair
Individuals with tendon, ligament, or muscle injuries seeking to support recovery timelines under physician supervision.
GI Health
Individuals with inflammatory bowel conditions or gut barrier concerns where GI mucosal support may be clinically appropriate.
Performance Recovery
High-output athletes or executives managing accumulated physical stress who require physician-supervised recovery support.
Longevity Stack
Individuals with existing longevity protocols seeking physician-reviewed additions for systemic tissue health support.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical settings. Individual outcomes may differ significantly. These are not guarantees. Results vary by individual physiology, protocol duration, dosing, and adherence.
Dosing is determined individually by your assigned physician based on your health intake, goals, and clinical profile. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
250–500 mcg/day
Administration
Subcutaneous or oral
Duration
4–12 weeks (physician-determined)
Frequency
Once daily (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.
Thymosin Beta-4 fragment studied alongside BPC-157 in tissue repair contexts.
More Information →Copper-binding peptide associated with tissue regeneration and anti-inflammatory activity.
More Information →Tripeptide studied for gut barrier support and GI inflammation modulation.
More Information →